Créer ou développer une activité en Belgique ou au Luxembourg

This seminar introduces to all tax, commercial and social law aspects with regard to the companies that want to do business in Belgium or in Luxembourg.L’Union européenne offre un espace extrêmement attractif pour les entreprises qui souhaitent y créer ou développer des activités. Pour favoriser ce développement, l’Union européenne a mis en place une réglementation qui vise à faciliter les échanges commerciaux et à supprimer les entraves à ces échanges. L’objectif de ce séminaire est d’examiner à la lumière de ces libertés les différentes étapes qu’il y a lieu d’observer pour créer ou développer une activité sur le territoire belge et sur celui du Grand-Duché du Luxembourg. Le séminaire s’articulera autour des thèmes suivants : Position du problème et aperçu de la jurisprudence de la Cour de Justice des communautés européennes sur la liberté d’établissement, la liberté de prestations de services, la liberté de circulation des travailleurs. Quelles sont les principales entraves au développement d’une activité ou d’une création d’entreprises et comment les éviter ou réagir ? Aperçu des formalités à accomplir au regard du droit des sociétés en fonction des choix stratégiques de l’investisseur. Constitution d’une société, d’une succursale, d’un bureau de représentation ou tout simplement le développement d’une activité sur ces territoires à partir d’un autre Etat ? Quelles sont les implications en droit des sociétés de ces choix ? Aperçu des formalités à accomplir au regard du droit fiscal (ISOC et IPP, Impôt des résidents et des non-résidents, TVA Transfrontalière) Aperçu des formalités à accomplir au regard du droit social (statuts social des administrateurs et affiliation aux organismes de sécurité sociale, mobilité internationale, déclaration de détachement, permis de travail, cartes professionnelles, sécurité sociale, déclaration de chantiers) Les orateurs insisteront sur les démarches concrètes et pratiques liées à la création, au développement d’une activité sur ces deux territoires

Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission

We conducted a multicenter, retrospective cohort study of hospitalized patients with serologically proven nephropathia epidemica (NE) living in Ardennes Department, France, during 2000–2014 to develop a bioclinical test predictive of severe disease. Among 205 patients, 45 (22.0%) had severe NE. We found the following factors predictive of severe NE: nephrotoxic drug exposure (p = 0.005, point value 10); visual disorders (p = 0.02, point value 8); microscopic or macroscopic hematuria (p = 0.04, point value 7); leukocyte count >10 × 109 cells/L (p = 0.01, point value 9); and thrombocytopenia 20 identified high-risk patients (45.3% had severe disease). If validated in future studies, this test could be used to stratify patients by severity in research studies and in clinical practice

Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort

International audienceAbstract Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD). Methods We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality. Results Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses. Conclusions COVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

International audienceThe aim of this study was to estimate the incidence of COVID-19 disease in the French national population of dialysis patients, their course of illness and to identify the risk factors associated with mortality. Our study included all patients on dialysis recorded in the French REIN Registry in April 2020. Clinical characteristics at last follow-up and the evolution of COVID-19 illness severity over time were recorded for diagnosed cases (either suspicious clinical symptoms, characteristic signs on the chest scan or a positive reverse transcription polymerase chain reaction) for SARS-CoV-2. A total of 1,621 infected patients were reported on the REIN registry from March 16th, 2020 to May 4th, 2020. Of these, 344 died. The prevalence of COVID-19 patients varied from less than 1% to 10% between regions. The probability of being a case was higher in males, patients with diabetes, those in need of assistance for transfer or treated at a self-care unit. Dialysis at home was associated with a lower probability of being infected as was being a smoker, a former smoker, having an active malignancy, or peripheral vascular disease. Mortality in diagnosed cases (21%) was associated with the same causes as in the general population. Higher age, hypoalbuminemia and the presence of an ischemic heart disease were statistically independently associated with a higher risk of death. Being treated at a selfcare unit was associated with a lower risk. Thus, our study showed a relatively low frequency of COVID-19 among dialysis patients contrary to what might have been assumed